SCHEMBL13030152

SCHEMBL13030152

O=[N+]([O-])c1ccc2c(cnn2C2CC(O)C(CO)O2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 1/20 0.47
▸ GLS O94925 1/20 0.45
▸ ADRB1 P08588 1/20 0.39
▸ DNMT1 P26358 1/20 0.39
▸ TYMS P04818 1/20 0.38
▸ ADRA2A P08913 1/20 0.37
▸ PNMT P11086 1/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ THPO P40225 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PMP22 Q01453 1/20 0.37
▸ RXRA P19793 1/20 0.37
▸ RXRB P28702 1/20 0.37
▸ RXRG P48443 1/20 0.37
▸ HBB P68871 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2946371 0.81 SLC29A1 (0.47) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL10183365 0.81 SLC29A1 (0.47) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL13030145 0.81 SLC29A1 (0.47) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL12732344 0.81 SLC29A1 (0.47) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL28902886 0.75 SLC29A1 (0.44) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL14395733 0.74 SLC29A1 (0.45) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL16217257 0.74 TK1 (0.50) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL2953389 0.74 TK1 (0.50) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL13264893 0.74 SLC29A1 (0.45) SLC29A1ADRB1DNMT1TYMSCYP1A2
SCHEMBL14395965 0.74 TK1 (0.46) SLC29A1ADRB1DNMT1TYMSCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292471-A1 PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES,PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME PANAGENE INC. (KR) 2010-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292471-A1 PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES,PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME ADAR, POLM, POLRMT SLC29A1 163/4885GLS 2014/4885ADRB1 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback